Proteases as prognostic markers in cancer

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Cancer invasion and metastasis are critical determinants of patient prognosis.
• Proteases, including urokinase plasminogen activator (uPA) and cathepsins, play a vital role in facilitating cancer cell invasion and matrix degradation.
• Identifying reliable prognostic markers is crucial for effective cancer management.

Purpose of the Study:

• To investigate the role of specific proteases as prognostic markers in various cancers.
• To evaluate the correlation between protease levels and patient outcomes, particularly in breast cancer.

Main Methods:

• Analysis of protease levels in primary tumors.
• Correlation of protease expression with clinical data, including prognosis and lymph node status.
• Review of existing studies on cathepsins and metalloproteases as prognostic indicators.

Main Results:

• Urokinase plasminogen activator (uPA) is a strong, independent prognostic marker in breast cancer, potentially indicating axillary node-negative disease.
• Elevated uPA levels are associated with poor prognosis in several other cancers, including gastric, colorectal, lung, bladder, cervical, and ovarian.
• Cathepsin D shows prognostic value in breast cancer, but results are conflicting, especially with immunocytochemistry.
• Cathepsin B, cathepsin L, and metalloproteases may offer prognostic data in certain cancers, though findings are preliminary.

Conclusions:

• Proteases are directly implicated in cancer cell invasion and metastasis, positioning them as potential prognostic markers.
• Urokinase plasminogen activator (uPA) demonstrates significant prognostic value across multiple cancer types, notably breast cancer.
• Further research is needed to clarify the prognostic utility of cathepsins and metalloproteases due to preliminary or conflicting data.